Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 244 Melanoma 141 Squamous Cell Carcinoma of Head and Neck 139 Parkinson Disease 4, Autosomal Dominant Lewy Body 119 Neoplasm Metastasis 105 Triple Negative Breast Neoplasms 96 Neoplasms 91 Lung Neoplasms 91 Breast Neoplasms 81 Colorectal Neoplasms 70 Carcinoma, Renal Cell 69 Head and Neck Neoplasms 59 Urinary Bladder Neoplasms 50 Stomach Neoplasms 48 Ovarian Neoplasms 46 Endometrial Neoplasms 46 Carcinoma, Transitional Cell 45 Carcinoma, Hepatocellular 35 Uterine Cervical Neoplasms 34 Pancreatic Neoplasms 34 Esophageal Neoplasms 27 Prostatic Neoplasms 26 Recurrence 25 Carcinoma, Squamous Cell 25 Carcinoma 25 Sarcoma 24 Brain Neoplasms 24 Glioblastoma 23 Hodgkin Disease 19 Cholangiocarcinoma 19

Interventions

atezolizumab 2 pembrolizumab 1 liposomal doxorubicin 1 Tumor Necrosis Factor-alpha 1 Gemcitabine 1 Cell Count 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenoviridae Infections × pembrolizumab × 1 year × Clear all

NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting

Adenoviridae Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡